TNF Alpha antibody | cA2
0.5 μg of Human Anti-TNFα Antibody, MCA6090 (infliximab biosimilar, research grade) and infliximab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.
Size exclusion chromatography (SEC) of Human Anti-Integrin Alpha 4 Antibody, MCA6104 (natalizumab biosimilar, research grade) and natalizumab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 μm; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 μl/min; inj. volume [μl]: 3; temp.: 25 °C; detection: 280 nm; sample: mAb (1 mg/ml).
A microtiter plate was coated overnight with Human Anti-Tocilizumab Antibody (clone AbD21362, HCA252) at a concentration of 1 μg/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of tocilizumab (therapeutic reference product) or Human Anti-IL6R Antibody, MCA6106 (tocilizumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Tocilizumab Antibody (clone AbD21338_hIgG1, HCA253) at a concentration of 2 μg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human anti TNF Alpha (Infliximab Biosimilar)
Anti-TNF Alpha Antibody is a non-therapeutic biosimilar of the monoclonal antibody drug infliximab (Remicade) for research use. It can be used in bioanalytical PK and ADA assays and for studying biological pathways affected by the drug.
- Product Type
- Monoclonal Antibody
- Clone
- cA2
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| MCA6090 | E | 0.2 mg |
Human Anti-TNF alpha Antibody is a research grade biosimilar of the monoclonal antibody drug infliximab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic infliximab antibody clone cA2.
This antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-infliximab antibodies, for example HCA214 and HCA216. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-infliximab antibody in IgG1 format as a reference standard, for example HCA213 or HCA233.
Infliximab, also known as Remicade, is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNF alpha and acts by blocking the binding of TNF alpha to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.
This product is NOT FOR THERAPEUTIC USE.
View a summary of supporting anti-infliximab antibody products
This antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-infliximab antibodies, for example HCA214 and HCA216. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-infliximab antibody in IgG1 format as a reference standard, for example HCA213 or HCA233.
Infliximab, also known as Remicade, is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNF alpha and acts by blocking the binding of TNF alpha to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.
This product is NOT FOR THERAPEUTIC USE.
View a summary of supporting anti-infliximab antibody products
Product Details
- Target Species
- Human
- Product Form
- Human IgG1 (kappa) antibody - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.02% Proclin 300
- Immunogen
- Human TNFα
- Purity
- >98% by SDS PAGE
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
More Information
- Licensed Use
- For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
- Regulatory
- For research purposes only
Applications of TNF Alpha antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Infliximab | HCA212 | 0.1 mg | E | ||
| Human anti Infliximab | HCA213 | 0.1 mg | E | ||
| Human anti Infliximab:HRP | HCA213P | 0.1 mg | E | ||
| Human anti Infliximab | HCA214 | 0.1 mg | E | ||
| Human anti Infliximab | HCA215 | 0.1 mg | E | ||
| Human anti Infliximab | HCA216 | 0.1 mg | E | ||
| Human anti Infliximab:HRP | HCA216P | 0.1 mg | E | ||
| Human anti Infliximab | HCA233 | 0.1 mg | E | ||
| Human anti Infliximab | HCA234 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK001P | 1 Conjugation For 400µg Antibody | CJ |
